Skip to main content
. 2017 Oct 27;8(61):104206–104215. doi: 10.18632/oncotarget.22171

Figure 5. Overexpression of miR-216b sensitizes NSCLC to cisplatin treatment in vivo.

Figure 5

(A) Nude mice were inoculated with miR-216b-overexpressed or control A549 cells, followed by administration with cisplatin (2 mg/kg, twice a week). 28 days later, mice were killed and the tumors were resected and weighted. *P<0.05 vs. control A549 + cisplatin group. #P<0.05 vs. miR-216-A549 group. (B) Expression levels of c-Jun, Bcl-xl and miR-216b in resected tumors were evaluated by western blot analysis. *P<0.05 vs. control A549 group. #P<0.05 vs. control A549 + cisplatin group.